Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 1.00 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 4/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.36 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22716184 | 0.88 | ATR (0.78) | ATRCYP17A1POLBLCKMAPKAPK2 | |
| SCHEMBL29847807 | 0.88 | ATR (0.78) | ATRCYP17A1POLBLCKKDM4E | |
| SCHEMBL16514014 | 0.88 | ATR (0.78) | ATRCYP17A1POLBLCKKDM4E | |
| SCHEMBL29439835 | 0.88 | ATR (0.78) | ATRCYP17A1POLBLCKMAPKAPK2 | |
| SCHEMBL18096187 | 0.85 | ATR (0.74) | ATRCYP17A1POLBLCKMAPKAPK2 | |
| SCHEMBL29439800 | 0.84 | ATR (0.73) | ATRCYP17A1POLBLCKCA12 | |
| SCHEMBL26656448 | 0.84 | ATR (0.72) | ATRCYP17A1POLBLCKPSMD14 | |
| SCHEMBL1699175 | 0.82 | ATR (0.69) | ATRCYP17A1POLBLCKCA12 | |
| SCHEMBL1253908 | 0.81 | ATR (0.67) | ATRCYP17A1POLBLCKGAA | |
| SCHEMBL30418941 | 0.81 | ATR (0.67) | ATRCYP17A1POLBLCKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-20 | — | — | US | disclosed |
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-20 | — | — | US | disclosed |
| CN-110204544-B | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-110256427-B | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-3395818-B1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma AG (DE) | 2021-09-22 | — | — | EP | disclosed |
| EP-3395818-B1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma AG (DE) | 2021-09-22 | — | — | EP | disclosed |
| US-20200383991-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-12-10 | — | — | US | disclosed |
| US-20200383991-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-12-10 | — | — | US | disclosed |
| US-10772893-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-09-15 | — | — | US | disclosed |
| US-10772893-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-09-15 | — | — | US | disclosed |
| EP-3177619-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2017-06-14 | — | — | EP | disclosed |
| CN-106795156-A | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2017-05-31 | — | — | CN | disclosed |
| US-9549932-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-24 | — | — | US | disclosed |
| US-9549932-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-24 | — | — | US | disclosed |
| US-9549932-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-24 | — | — | US | disclosed |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| WO-2016020320-A1 | 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016020320-A1 | 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | POLQ, CCND2, NRAS | ATR 3508/4885CYP17A1 1918/4885POLB 40/4885 |
| US-20200383991-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | ATR 3508/4885CYP17A1 1918/4885POLB 40/4885 |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | ATR 3508/4885CYP17A1 1918/4885POLB 40/4885 |
| US-10772893-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | POLQ, CCND2, NRAS | ATR 3508/4885CYP17A1 1918/4885POLB 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.